Prof. Tim Walsh has been studying AMR mechanisms for over 25 years, and publishes regularly in Nature and Lancet journals. He is director of BARNARDS, a Gates Foundation project on AMR, prospectively examining the burden of neonatal sepsis in Pakistan, India, Bangladesh, Rwanda, South Africa, Nigeria (Abuja and Kano) and Ethiopia. Follow up programs include assessing the risks of still-born infants and maternal care in sub-Sahara Africa and assessing the impact of access to affordable antibiotics. Studies in Pakistan include the role of insects in post-surgical infections and the illegal global trade of colistin in agriculture. In addition to BARNARDS, he also has neonatal AMR studies in Pakistan (Karachi, Faisalabad and Peshawar) and Nigeria (Kano, Sokoto and Ebonyi), and has collaborative studies with MSF in Niger (Clean Kids Study) and has facilitated the design and construction of the MSF Microbiology/AMR lab in Jordan/Syria. He also has clinical studies examining the burden of AMR in the community and hospitals San Paolo (Brazil), Phitsanulok (Thailand) and Tanta (Egypt).
Walsh is also PI of DETER-XDR-CHINA, a study examining the spread and burden of AMR in public health sectors and hospitals in 30 provinces in China. He is also PI of CUT-SEC, a ‘one-health” project in China and Thailand.
Recently, he has moved to University of Oxford, and co-established the Ineos Oxford Institute of Antimicrobial Research (£100M gift from Ineos) where he is Co-Director and Biology Lead. Walsh has also been appointed to the Fleming Fund expert advisory panel – a rolling UK government AMR capacity building program in LMICs. He is also advisor to the Chinese CDC and MSF. Walsh is also advisor to the Foundation Merieux AMR teaching program and has recently been appointed on the WHO Strategic and Technical Advisory Group for Antimicrobial Resistance (STAG-AMR). In 2020, he was awarded an O.B.E for “Microbiology and International Development”.